Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

APRE holding history

Aprea Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

APRE overviewAll 13F holders of APREFull Q2 2026 holdings

Shares (Q2 2026)
3
Value
$2
% of portfolio
<0.1%
Quarters held
21
Since Q1 2021
Holdings of APRE by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20263$2<0.1%−2,150−99.9%ReducedHolders
Q1 20262,153$1.64K<0.1%−308−12.5%ReducedHolders
Q4 20252,461$2.10K<0.1%+2,458+81,933.3%AddedHolders
Q3 20253$4<0.1%−5−62.5%ReducedHolders
Q2 20258$13<0.1%+5+166.7%AddedHolders
Q1 20253$6<0.1%−5,932−99.9%ReducedHolders
Q4 20245,935$19.5K<0.1%+5,932+197,733.3%AddedHolders
Q3 20243$8<0.1%00.0%UnchangedHolders
Q2 20243$12<0.1%00.0%UnchangedHolders
Q1 20243$20<0.1%00.0%UnchangedHolders
Q4 20233$14<0.1%00.0%UnchangedHolders
Q3 20233$13<0.1%00.0%UnchangedHolders
Q2 20233$9<0.1%−671−99.6%ReducedHolders
Q1 2023674$2.99K<0.1%−613−47.6%ReducedConverted for a 1-for-20 splitHolders
Q4 202225,739$8.49K<0.1%+19,797+333.2%AddedHolders
Q3 20225,942$4.00K<0.1%−4,390−42.5%ReducedHolders
Q2 202210,332$8.00K<0.1%+5,072+96.4%AddedHolders
Q1 20225,260$10.0K<0.1%+5,185+6,913.3%AddedHolders
Q4 202175$00.0%+75NewHolders
Q3 20210$00.0%−1,322−100.0%Sold outHolders
Q2 20211,322$6.00K<0.1%−1,163−46.8%ReducedHolders
Q1 20212,485$13.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.